NEW YORK (GenomeWeb) – Biodesix today announced that its VeriStrat test has received a positive coverage decision from CareFirst Blue Cross Blue Shield.

VeriStrat is a blood-based proteomic test that helps guide treatment decisions for patients with non-small cell lung cancer.

CareFirst announced its position to extend coverage for the VeriStrat test in March and published a positive coverage policy earlier this week on its website, Biodesix said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.